Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Capurro, Valeria ^a   Busquet, Perrine ^a   Lopes, Joao Pedro ^a   Bertorelli, Rosalia ^a   Tarozzo, Glauco ^a   Bolognesi, Maria Laura ^b   Piomelli, Daniele ^a,c   Reggiani, Angelo ^a   Cavalli, Andrea ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMOQUIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EPISODIC MEMORY; EXPERIMENTAL TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; MAZE TEST; MORRIS WATER MAZE; MOUSE; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TASK; OPEN FIELD TEST; PASSIVE AVOIDANCE; PSYCHOMOTOR PERFORMANCE; RAT; ROTAROD TEST; T MAZE;

ALKANES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ETHYLAMINES; FEMALE; MALE; MAZE LEARNING; MEMORY; MICE; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; RATS;

EID: 84874153672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056870     Document Type: Article

References (50)

1. Lau LF, Brodney MA, (2008) Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. Top Med Chem 2: 1-24.
2. Bartus RT, Dean RL III, Beer B, Lippa AS, (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-414.
3. Stone JG, Casadesus G, Gustaw-Rothenberg K, Siedlak SL, Wang X, et al. (2011) Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis 2: 9-23.
4. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
5. Karran E, Mercken M, De Strooper B, (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
6. Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, et al. (2011) Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets 10: 149-162.
7. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, et al. (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20 (Suppl 2):: S609-631.
8. Smith RA, Murphy MP, (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 1201: 96-103.
9. Gutzmann H, Hadler D, (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54: pp. 301-310.
10. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, et al. (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179: 2071-2082.
11. Tran HT, LaFerla FM, Holtzman DM, Brody DL, (2011) Controlled cortical impact traumatic brain injury in 3×Tg-AD mice causes acute intra-axonal amyloid-beta accumulation and independently accelerates the development of tau abnormalities. J Neurosci 31: 9513-9525.
12. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, et al. (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51: 347-372.
13. Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C, (2009) Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol 13: 303-308.
14. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, et al. (2007) A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl 46: 3689-3692.
15. Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, et al. (2011) Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. Curr Top Med Chem 11: 2797-2806.
16. Bolognesi ML, Cavalli A, Melchiorre C, (2009) Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 6: 152-162.
17. Cavalli A, Bolognesi ML (2012) Multitargeted Drugs for Treatment of Alzheimer's Disease. Polypharmacology in Drug Discovery: John Wiley & Sons, Inc. pp. 441-458.
18. Mohamed T, Yeung JC, Rao PP, (2011) Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Abeta-aggregation inhibitors: Synthesis and biological evaluation. Bioorg Med Chem Lett 21: 5881-5887.
19. Bolognesi ML, Bartolini M, Tarozzi A, Morroni F, Lizzi F, et al. (2011) Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg Med Chem Lett 21: 2655-2658.
20. Paxinos G, Franklin KBJ (2007) Mouse Brain in Stereotaxic Coordinates: Academic press.
21. Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, et al. (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18: 143-148.
22. Morgan D, Munireddy S, Alamed J, DeLeon J, Diamond DM, et al. (2008) Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. J Alzheimers Dis 15: 605-614.
23. Spowart-Manning L, van der Staay FJ, (2004) The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 151: 37-46.
24. Vorhees CV, Williams MT, (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
25. Bevins RA, Besheer J, (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat Protoc 1: 1306-1311.
26. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, et al. (1996) Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277: 728-738.
27. Agostinho P, Oliveira CR, (2003) Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides. Eur J Neurosci 17: 1189-1196.
28. Bolognesi ML, Banzi R, Bartolini M, Cavalli A, Tarozzi A, et al. (2007) Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem 50: 4882-4897.
29. Kanski J, Sultana R, Klunk W, Butterfield DA, (2003) Antioxidant activity of X-34 in synaptosomal and neuronal systems. Brain Res 988: 173-179.
30. Resende R, Ferreiro E, Pereira C, Resende de Oliveira C, (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155: 725-737.
31. Snowden JS, Thompson JC, Stopford CL, Richardson AM, Gerhard A, et al. (2011) The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 134: 2478-2492.
32. Tulving E (1972) In:Tulving E, Donaldson W, editors. Organization of Memory: Academic Press pp. 381-402.
33. Sharma S, Rakoczy S, Brown-Borg H, (2010) Assessment of spatial memory in mice. Life Sci 87: 521-536.
34. O'Keefe J, Nadel L (1978) The Hippocampus as a Cognitive Map.: Oxford University Press.
35. Gacar N, Mutlu O, Utkan T, Komsuoglu Celikyurt I, Gocmez SS, et al. (2011) Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol Biochem Behav 99: 316-323.
36. Dere E, Huston JP, De Souza Silva MA, (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31: 673-704.
37. Tsuji M, Takeda H, Matsumiya T, (2003) Modulation of passive avoidance in mice by the 5-HT1A receptor agonist flesinoxan: comparison with the benzodiazepine receptor agonist diazepam. Neuropsychopharmacology 28: 664-674.
38. Mazzola C, Micale V, Drago F, (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477: 219-225.
39. Van Dam D, De Deyn PP, (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5: 956-970.
40. Kim DH, Jung WY, Park SJ, Kim JM, Lee S, et al. (2010) Anti-amnesic effect of ESP-102 on Abeta(1-42)-induced memory impairment in mice. Pharmacol Biochem Behav 97: 239-248.
41. Meunier J, Villard V, Givalois L, Maurice T, (2013) The gamma-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Abeta(1-42) seeding and short-term memory deficits in the Abeta(25-35) mouse model of Alzheimer's disease. Eur J Pharmacol 698: 193-199.
42. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45-53.
43. Meunier J, Ieni J, Maurice T, (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149: 998-1012.
44. Axelsen PH, Komatsu H, Murray IV, (2011) Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology (Bethesda) 26: 54-69.
45. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ, (2000) Role of quinones in toxicology. Chem Res Toxicol 13: 135-160.
46. Valgimigli L, Amorati R, Fumo MG, DiLabio GA, Pedulli GF, et al. (2008) The unusual reaction of semiquinone radicals with molecular oxygen. J Org Chem 73: 1830-1841.
47. Raina AK, Templeton DJ, Deak JC, Perry G, Smith MA, (1999) Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Rep 4: 23-27.
48. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C, (2004) Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 25: 63-69.
49. Wang Y, Santa-Cruz K, DeCarli C, Johnson JA (2000) NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease. 525-531 p.
50. Zhang HY, (2005) One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 579: 5260-5264.